The historical rank and industry rank for Bio-Path Holdings's Net Margin % or its related term are showing as below:
BPTH's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -148.41 * Ranked among companies with meaningful Net Margin % only.
Bio-Path Holdings Net Margin % Historical Data
The historical data trend for Bio-Path Holdings's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bio-Path Holdings's Net Margin %
For the Biotechnology subindustry, Bio-Path Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's Net Margin % falls into.
Bio-Path Holdings Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Bio-Path Holdings's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Path Holdings (NAS:BPTH) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bio-Path Holdings Net Margin % Related Terms
Thank you for viewing the detailed overview of Bio-Path Holdings's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bio-Path Holdings (Bio-Path Holdings) Business Description
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BPTH has been successfully added to your 